Highly Expressing SCARA5 Promotes Proliferation and Migration of Esophageal Squamous Cell Carcinoma

Kawuli Jumai, Tangjuan Zhang, Bingzhang Qiao, Julaiti Ainiwaer, Haiping Zhang, Zhichao Hou, Idris Awut, Madinyat Niyaz, Liwei Zhang, Ilyar SheyhidinJournal of Immunology Research 2022 · DOI

TL;DR

This study identifies SCARA5 as a novel, highly expressed gene in esophageal squamous cell carcinoma (ESCC) that promotes tumor cell proliferation and migration. Unlike its previously reported tumor-suppressive role in other cancers, SCARA5 acts as an oncogene in ESCC, suggesting it could be a valuable therapeutic target.

What Problem Does This Paper Address?

Esophageal cancer (EC) is a significant global health burden, with esophageal squamous cell carcinoma (ESCC) being a prevalent subtype. While the upstream gene THSD7A has been implicated in ESCC progression, its downstream functional genes and their specific roles in ESCC remain largely unexplored. This paper aims to identify and characterize these downstream genes, focusing on their impact on ESCC development and progression, and to understand why SCARA5, known as a tumor suppressor in other contexts, behaves differently in ESCC.

Methods

The researchers employed a multi-pronged approach to identify and validate SCARA5's role in ESCC. They began by using quantitative reverse-transcription polymerase chain reaction (qRT-PCR) and Celigo high-content screening (HCS) to identify downstream genes of THSD7A. Promising candidates were then further analyzed using western blot and immunohistochemistry (IHC) to assess protein expression. Functional studies in vitro included cell cycle and apoptosis assays, cell invasion assays, and wound healing assays to evaluate the impact of SCARA5 on malignant behaviors. In vivo experiments utilized xenografted athymic nude-mouse models to assess tumor growth. To investigate potential reasons for SCARA5's differential function, exon sequencing was performed on ESCC cell lines.

Datasets

The study utilized tissue microarrays containing samples from 100 ESCC cases and 80 paired normal adjacent tissues for IHC analysis. Human ESCC cell lines (Eca109, EC9706, and TE-1) were used for in vitro experiments. For in vivo studies, BALB/c nude mice were used to establish xenograft models. The researchers also referenced existing literature on liver cancer (LC) cell lines (Hep 3B and Huh-7) for comparative analysis.

Key Insights and Ideas

  • SCARA5 as an ESCC Oncogene: Contrary to its established role as a tumor suppressor in other cancers like liver and breast cancer, SCARA5 acts as a proto-oncogene in ESCC, promoting proliferation and migration. This highlights the context-dependent nature of gene function in cancer.
  • THSD7A-SCARA5 Axis: The study establishes SCARA5 as a direct downstream driving gene of THSD7A in ESCC, suggesting a coordinated signaling pathway that fuels tumor growth.
  • Differential Gene Function: The stark contrast in SCARA5's function between ESCC and liver cancer underscores the complexity of cancer biology and the need for tissue-specific investigations.
  • Potential Therapeutic Target: The findings position SCARA5 as a promising diagnostic and therapeutic target for ESCC, potentially in combination with its upstream regulator, THSD7A.

Key Results

  • SCARA5 was identified as a key downstream gene of THSD7A in ESCC.
  • Knockdown of SCARA5 significantly inhibited proliferation, migration, and induced apoptosis in ESCC cell lines (Eca109, EC9706, TE-1) in vitro.
  • In vivo experiments showed that SCARA5 knockdown suppressed subcutaneous tumor growth in nude mice.
  • IHC analysis revealed significantly higher SCARA5 expression in ESCC tissues compared to normal adjacent tissues.
  • Univariate and multivariate Cox analyses indicated that while SCARA5 expression itself was not a significant prognostic factor, tumor volume and T classification were independent prognostic factors.
  • Experiments in liver cancer cell lines (Hep 3B and Huh-7) confirmed SCARA5's tumor-suppressive role, contrasting with its oncogenic function in ESCC.
  • Exon sequencing identified mutations in SCARA5 in ESCC cell lines, but further experiments with wild-type SCARA5 confirmed its oncogenic role in ESCC, suggesting mutations might not be the sole cause of the functional shift.

Limitations and Future Work

The authors acknowledge several limitations:

  • Sample Size: The relatively small sample size of ESCC tissues might have led to biased conclusions regarding the correlation between SCARA5 expression and clinicopathological parameters.
  • Antibody Validation: The need for thorough validation of primary antibodies to ensure reproducibility is mentioned.
  • Tissue Heterogeneity: The use of tissue microarrays might not fully capture the heterogeneity of SCARA5 expression within individual tumors.

Future work should focus on:

  • Confirming these observations in larger patient cohorts.
  • Further investigating the mechanisms by which SCARA5 promotes ESCC, particularly its interaction with signaling pathways like mTOR and FAK.
  • Exploring the precise reasons for SCARA5's opposing roles in different cancer types, potentially involving epigenetic modifications or interactions with other cellular components.
  • Developing therapeutic strategies targeting the THSD7A-SCARA5 axis for ESCC treatment.

Summary updated

Abstract

<i>SCARA5</i> was related to the development and occurrence of ESCC. Our findings suggested that it was a potentially diagnostic individualized therapeutic target for ESCC in the future and that its application could possibly be combined with that of upstream THSD7A gene.
BibTeX
@article{jumai2022highly,
  author = {Kawuli Jumai and Tangjuan Zhang and Bingzhang Qiao and Julaiti Ainiwaer and Haiping Zhang and Zhichao Hou and Idris Awut and Madinyat Niyaz and Liwei Zhang and Ilyar Sheyhidin},
  title = {{Highly Expressing SCARA5 Promotes Proliferation and Migration of Esophageal Squamous Cell Carcinoma}},
  journal = {Journal of Immunology Research},
  year = {2022},
  doi = {10.1155/2022/2555647},
}
Figure